vs
Side-by-side financial comparison of Charles River Laboratories (CRL) and Moderna (MRNA). Click either name above to swap in a different company.
Moderna is the larger business by last-quarter revenue ($1.0B vs $994.2M, roughly 1.0× Charles River Laboratories). Moderna runs the higher net margin — -19.7% vs -27.8%, a 8.1% gap on every dollar of revenue. On growth, Charles River Laboratories posted the faster year-over-year revenue change (-0.8% vs -45.4%). Charles River Laboratories produced more free cash flow last quarter ($58.6M vs $-880.0M). Over the past eight quarters, Charles River Laboratories's revenue compounded faster (-0.9% CAGR vs -45.0%).
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
CRL vs MRNA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $994.2M | $1.0B |
| Net Profit | $-276.6M | $-200.0M |
| Gross Margin | — | 79.6% |
| Operating Margin | -28.5% | -25.6% |
| Net Margin | -27.8% | -19.7% |
| Revenue YoY | -0.8% | -45.4% |
| Net Profit YoY | -28.9% | -1638.5% |
| EPS (diluted) | $-5.57 | $-0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $994.2M | — | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $984.2M | — | ||
| Q4 24 | $1.0B | $966.0M | ||
| Q3 24 | $1.0B | $1.9B | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $1.0B | — |
| Q4 25 | $-276.6M | — | ||
| Q3 25 | $54.4M | $-200.0M | ||
| Q2 25 | $52.3M | — | ||
| Q1 25 | $25.5M | — | ||
| Q4 24 | $-214.5M | $-1.1B | ||
| Q3 24 | $69.7M | $13.0M | ||
| Q2 24 | $94.1M | — | ||
| Q1 24 | $73.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 79.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 23.5% | ||
| Q3 24 | 34.6% | 72.4% | ||
| Q2 24 | 34.5% | — | ||
| Q1 24 | 34.1% | — |
| Q4 25 | -28.5% | — | ||
| Q3 25 | 13.3% | -25.6% | ||
| Q2 25 | 9.7% | — | ||
| Q1 25 | 7.6% | — | ||
| Q4 24 | -16.7% | -129.0% | ||
| Q3 24 | 11.6% | -3.8% | ||
| Q2 24 | 14.8% | — | ||
| Q1 24 | 12.5% | — |
| Q4 25 | -27.8% | — | ||
| Q3 25 | 5.4% | -19.7% | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -21.4% | -115.9% | ||
| Q3 24 | 6.9% | 0.7% | ||
| Q2 24 | 9.2% | — | ||
| Q1 24 | 7.2% | — |
| Q4 25 | $-5.57 | — | ||
| Q3 25 | $1.10 | $-0.51 | ||
| Q2 25 | $1.06 | — | ||
| Q1 25 | $0.50 | — | ||
| Q4 24 | $-4.17 | $-2.91 | ||
| Q3 24 | $1.33 | $0.03 | ||
| Q2 24 | $1.74 | — | ||
| Q1 24 | $1.30 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $213.8M | $1.1B |
| Total DebtLower is stronger | $2.1B | — |
| Stockholders' EquityBook value | $3.2B | $9.3B |
| Total Assets | $7.1B | $12.1B |
| Debt / EquityLower = less leverage | 0.68× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $213.8M | — | ||
| Q3 25 | $207.1M | $1.1B | ||
| Q2 25 | $182.8M | — | ||
| Q1 25 | $229.4M | — | ||
| Q4 24 | $194.6M | $1.9B | ||
| Q3 24 | $210.2M | $1.6B | ||
| Q2 24 | $179.2M | — | ||
| Q1 24 | $327.0M | — |
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.7B | — |
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.4B | $9.3B | ||
| Q2 25 | $3.4B | — | ||
| Q1 25 | $3.2B | — | ||
| Q4 24 | $3.5B | $10.9B | ||
| Q3 24 | $3.8B | $11.9B | ||
| Q2 24 | $3.7B | — | ||
| Q1 24 | $3.6B | — |
| Q4 25 | $7.1B | — | ||
| Q3 25 | $7.5B | $12.1B | ||
| Q2 25 | $7.6B | — | ||
| Q1 25 | $7.6B | — | ||
| Q4 24 | $7.5B | $14.1B | ||
| Q3 24 | $8.0B | $15.8B | ||
| Q2 24 | $7.9B | — | ||
| Q1 24 | $8.2B | — |
| Q4 25 | 0.68× | — | ||
| Q3 25 | 0.64× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.79× | — | ||
| Q4 24 | 0.65× | — | ||
| Q3 24 | 0.62× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.73× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $147.5M | $-847.0M |
| Free Cash FlowOCF − Capex | $58.6M | $-880.0M |
| FCF MarginFCF / Revenue | 5.9% | -86.6% |
| Capex IntensityCapex / Revenue | 8.9% | 3.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $518.5M | $-1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $147.5M | — | ||
| Q3 25 | $213.8M | $-847.0M | ||
| Q2 25 | $204.6M | — | ||
| Q1 25 | $171.7M | — | ||
| Q4 24 | $159.4M | $825.0M | ||
| Q3 24 | $251.8M | $-1.6B | ||
| Q2 24 | $193.5M | — | ||
| Q1 24 | $129.9M | — |
| Q4 25 | $58.6M | — | ||
| Q3 25 | $178.2M | $-880.0M | ||
| Q2 25 | $169.3M | — | ||
| Q1 25 | $112.4M | — | ||
| Q4 24 | $83.7M | $303.0M | ||
| Q3 24 | $213.1M | $-1.7B | ||
| Q2 24 | $154.0M | — | ||
| Q1 24 | $50.7M | — |
| Q4 25 | 5.9% | — | ||
| Q3 25 | 17.7% | -86.6% | ||
| Q2 25 | 16.4% | — | ||
| Q1 25 | 11.4% | — | ||
| Q4 24 | 8.4% | 31.4% | ||
| Q3 24 | 21.1% | -92.2% | ||
| Q2 24 | 15.0% | — | ||
| Q1 24 | 5.0% | — |
| Q4 25 | 8.9% | — | ||
| Q3 25 | 3.5% | 3.2% | ||
| Q2 25 | 3.4% | — | ||
| Q1 25 | 6.0% | — | ||
| Q4 24 | 7.5% | 54.0% | ||
| Q3 24 | 3.8% | 8.1% | ||
| Q2 24 | 3.8% | — | ||
| Q1 24 | 7.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 3.93× | — | ||
| Q2 25 | 3.91× | — | ||
| Q1 25 | 6.74× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.61× | -120.46× | ||
| Q2 24 | 2.06× | — | ||
| Q1 24 | 1.78× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRL
| Discovery And Safety Assessment Segment | $591.6M | 60% |
| Manufacturing Support Segment | $196.4M | 20% |
| Transferred At Point In Time | $108.0M | 11% |
| Transferred Over Time | $98.3M | 10% |
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
